Hoth Therapeutics, Inc. (HOTH) is a pre-revenue clinical-stage pharmaceutical company with a balance sheet that, under a liquidation lens, shows thin but positive residual equity recovery — approximately $6.2M in reported stockholders' equity against $7.6M total assets and $1.5M total liabilities as of December 31, 2025. Adjusted for liquidation haircuts, the picture deteriorates: cash of $6.25M recovers at par, the crypto asset ($191K fair value, already marked-to-market) recovers at par, prepaid expenses ($1.07M gross) recover at best 50 cents on the dollar, and the ROU asset ($4.7K net) and investment in joint venture ($36.8K) contribute negligibly. Intangibles embedded in prepaid (deferred offering costs $57K, insurance $40K) are partially recoverable; capitalized patents acquired in January 2025 for $1.25M cash-plus-stock are carried in noncurrent prepaids and would recover at 0% under the intangible haircut convention. Liabilities total $1.45M (all current: AP $824K, accruals $623K, lease liability $6K), all settled at face. MFFAIS reports a CLV/LLV/OLV of approximately $4.8M, consistent with cash-dominated asset base minus working capital liabilities and haircut on non-cash current assets. Net loss accelerated to $12.47M in 2025 from $8.19M in 2024, a 52% increase driven by higher G&A ($6.41M vs. implied lower prior year) and persistent R&D spend ($5.95M). Cash burn through operations was $9.8M for the year; offsetting financing inflows included $5.63M from the January 2025 April 2024 Inducement Warrant exercise and $4.12M ATM proceeds, leaving ending cash of $6.25M versus $7.04M at December 31, 2024 (implied from $793K net decrease). The company holds a $58.7M federal NOL carryforward, fully offset by a $21.26M valuation allowance — zero recovery value under liquidation. Post-period, the company liquidated all crypto holdings (February 4, 2026) and raised an additional $706K via ATM through March 26, 2026. The operating lease expires February 28, 2026 with a January 2026 one-year renewal executed, adding a modest near-term lease liability not yet on the December 31, 2025 balance sheet. CEO employment agreement executed August 2025 creates a contingent severance obligation of up to 24–36 months base salary ($550K/year) plus COBRA — not accrued on balance sheet but would constitute a liquidation claim if termination triggered upon wind-down. Filing discusses the OBBBA Section 174 R&D expensing election in MD&A but the net DTA impact is zero given full valuation allowance.
▼ Community Notes